Loading
A phase 1/2 trial of liposomal irinotecan, fluorouracil (5-FU), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel), nab-paclitaxel and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment is a phase 1/2, interventional study registered as NCT06370754 by Fudan University, with a registry enrolment figure of 117 participants, started 2024-04-30 and due to reach its primary completion in 2026-04-30. Interventions recorded: JS001; JS004; JS007; JS015; Irinotecan Liposome Injection; 5-Fluorouracil (5-FU); Leucovorin (LV); Nab paclitaxel; Gemcitabine. Conditions listed: Pancreatic Cancer. Primary outcome: Incidence of dose-limiting toxicity (DLT) (phase IB); Objective Response Rate (ORR) (phase II). Pancreatic eligibility wording from the registry: "* Patients with locally advanced unresectable or metastatic pancreatic cancer confirmed by histopathology or cytopathology (islet cell tumor is not eligible for inclusion) who meet the following requirements:". Sites: China. No results are recorded here; the registry entry is the source.
Shares Liposomal irinotecan, FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Nab-paclitaxel, Fluorouracil (5-FU), Locally advanced unresectable pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Liposomal irinotecan, FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Nab-paclitaxel, Fluorouracil (5-FU), Locally advanced unresectable pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Locally advanced unresectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.